PolyPid (PYPD) Other Accumulated Expenses (2023 - 2026)
PolyPid (PYPD) posted Other Accumulated Expenses of $8000.0 for Q4 2025, down 65.22% sequentially from $23000.0 in Q4 2024, and down 65.22% YoY from $23000.0 in Q4 2024.
PolyPid (PYPD) Other Accumulated Expenses (2023 - 2026) Analysis & Trends
PolyPid has reported Other Accumulated Expenses for 3 years, with the latest figure at $8000.0 in Q4 2025.
- Quarterly Other Accumulated Expenses fell 65.22% year-over-year to $8000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8000.0 (down 65.22% YoY) and the FY2025 annual result came in at $8000.0, down 65.22% from the prior year.
- Other Accumulated Expenses eased to $8000.0 in Q4 2025 per PYPD's latest filing, from $23000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $23000.0 in Q4 2024 and troughed at $8000.0 in Q4 2025.
- A 3-year average of $16333.3 and a median of $18000.0 in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses grew 27.78% in 2024, then tumbled 65.22% in 2025.
- Over 3 years, Other Accumulated Expenses stood at $18000.0 in 2023, then increased by 27.78% to $23000.0 in 2024, then sank by 65.22% to $8000.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $8000.0, $23000.0, and $18000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 401,000.00 |
| Dec 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Dec 31, 2023 | 18,000.00 |